NCT01312311Unknown2 期
Phase II Trial of Cisplatin Plus Weekly Docetaxel as the First-line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- objective response rate
研究概览
简要总结
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed nasopharyngeal cancer
- •chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
- •at least one measurable lesion
排除标准
- •other cancer
- •docetaxel hypersentitivity history
- •severe heart or pulmonary disease
研究组 & 干预措施
weekly docetaxel and cisplatin
Experimental
Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
干预措施: Docetaxel, Cisplatin (Drug)
结局指标
主要结局
objective response rate
时间窗: 6 months after the enrollment of the last patients
次要结局
- number of patients with adverse events(simultaneously when the analysis of primary endpoint)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Weekly Docetaxel Plus Cisplatin or Oxaliplatin for AGCStomach NeoplasmStage IVRecurrentNCT00510107Gachon University Gil Medical Center90
已完成
1 期
Phase I/II study of biweekly docetaxel, cisplatin, and S-1 combination neoadjuvant chemotherapy in patients with stage III gastric cancergastric cancerJPRN-UMIN000011625Yokohama City University Medical Center51
终止
2 期
Study of Induction Docetaxel, Cisplatin and 5-FluorouracilSquamous Cell CarcinomaOral CancerNCT00400205Emory University14
已完成
1 期
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)Head and Neck NeoplasmsNCT00268671Sanofi45
终止
2 期
Study of Weekly DCF to Treat Advanced Gastric CancerGastric CancerNCT00568971Fudan University40